-
Researchers have long noted links between cancer and autoimmune rheumatic diseases. Naturally occurring or pharmacologically induced anti-tumor immune responses may lead to autoimmune diseases.
-
Treatment with the IL17 inhibitor secukinumab inhibits radiographic progression in patients with psoriatic arthritis: this promising result could be shown in the large FUTURE 5 trial.
-
In a post hoc analysis of two phase 3 trials, therapy with Sarilumab lowered HbA1c concentrations in diabetic and nondiabetic rheumatoid arthritis (RA) patients.
-
A study showed that low levels of vitamin D were associated with higher rates of end-stage renal disease in patients with Systemic Lupus Erythematosus (SLE).
-
According to new research findings, infants of rheumatoid arthritis (RA) patients using a biologic during pregnancy do not have an elevated risk of infections.
-
Crohn’s disease (CD) is a progressive disorder and the achievement of mucosal healing lowers the risk of necessary surgery, according to Julián Panés (Spain).
-
As early as week 2, patient-reported symptomatic improvements were achieved among UC patients treated with vedolizumab – including a combined reduction in defecation frequency and rectal blood loss. These findings underline the fast action of vedolizumab in treating UC, particularly when it is used as a first-line biological therapy.
-
Liquid biopsy is a new and very promising method for cancer diagnosis, prognosis and prediction. It has great advantages but also limitations. Large-scale evidence of its utility for the care of cancer patients is missing yet. What are the practical experiences up to now and which markers should be used?
-
The keynote lecture given by Robert Kurman was one of several highlights of the first joint IAP/ESP Congress in Cologne. With the development of a dualistic model of ovarian cancer a paradigm shift has occurred. What does this mean for the pathologist, the clinician and – most important – the patient?
-
“A wonderful opportunity to link the lab to the patients” Dr. Olanrewaju Ajetunmobi, Federal Medical Centre, Makurdi Benue State (Nigeria), on his impressions of the IAP/ESP Congress in Cologne. “Patiens are the same globally”, says Dr. Ajetunmobi, pathology resident from Nigeria. But in his country pathology has not the importance it deserves.
-
Interview with Prof. Julio Aguierre-Ghiso on the clinical impact of new insights into metastasis formation. Metastasis and primary tumor growth can be initiated simultaneously. Oncogenes and tumor suppressors alter mechanisms linked to cell movement and cell survival, before causing frank tumor growth.
-
esanum-interview with Prof. Reinhard Büttner, University Hospital Cologne (Germany), on the broad spectrum of pathology and the need of personal exchange. To span the entire bridge from basic pathology – the causal understanding of disease – to applied clinical diagnostic, predictive and evaluative pathology is a key issue of the IAP/ESP Congress 2016 in Cologne.
-
esanum-interview with Prof. Dr. Tibor Tot, Uppsala University (Sweden) on the role of pathology as a busy discipline in connection with breast cancer cases. “In an era of molecular medicine, genetic evaluation and new therapy modalities pathology is a central discipline in all these things.
-
Interview with Prof. Robert Osamura, Sanno Hospital, Tokyo (Japan), on recent developments in cytopathology. With gene-specific targeted cancer therapies the task for the pathologist has increased from the morphologic diagnosis to the genetic information that is needed for a personalized treatment.
-
Interview with Prof. Elisabeth Dequeker, University Leuven (Belgium), on her experiences with external quality assessment (EQA) schemes in pathology. Pathology labs that regularly participate in EQA schemes evidently improve their performance. Furthermore EQA can help to validate and implement new technologies.
-
Interview with Prof. Dietmar Schmidt, Co-President of the Joint IAP/ESP Congress 2016, on the premiere of a joint IAP/ESP congress.
-
Patients with severe Osteoarthritis (OA) benefit from a combination of optimisation of analgetics and a physical training program.
-
The prevalence of gout is increasing, despite good treatment options available. Under diagnosis, late diagnosis, undertreatment and discontinuation of treatment contribute to the rising incidence. These data were presented during an Outcome Science Session at the EULAR Annual Congress 2016 in London.
-
The Emerging EUlar NETwork (EMEUNET) is a network of young clinicians and researchers in Europe with the aim to improve education in rheumatology.
-
A newly developed method of evaluating the impact of different comorbidities in patients with psoriatic Arthritis (PsA) can be used to prospectively identify those PsA patients at greater risk of hospitalisation and premature death.
